Imatinib mesylate in Philadelphia chromo
β
E. Anders Kolb; Qiulu Pan; Marc Ladanyi; Peter G. Steinherz
π
Article
π
2003
π
John Wiley and Sons
π
English
β 177 KB
π 1 views
## Abstract ## BACKGROUND Initial treatment for adult patients with Philadelphia chromosomeβpositive (Ph[+]) chronic myelogenous leukemia (CML) now includes imatinib mesylate. However, to our knowledge, there are few data regarding imatinib safety, efficacy, and response monitoring in patients age